Mesoblast Limited (NASDAQ:MESO) Lowers Leverage And Accelerates Commercial Momentum
![]() |
Recent financing and independent clinical findings shift the company’s immediate posture toward balance-sheet repair and commercialization reinforcement, while valuation metrics remain stretched. |









